

FDA Responses to Action Items from October 27-28, 2020, Inter-governmental Working Meeting on Drug Compounding

FDA will seek to provide states more opportunities to interact with the agency on drug compounding matters. As part of this effort, FDA will:

- **Continue to join monthly executive calls held by the NABP, as possible and appropriate**
- **Explore additional virtual meeting opportunities with state boards of pharmacy to discuss and answer questions on current topics such as the MOU and compounding during the public health emergency**

FDA continues to work with NABP to expand opportunities to interact with the agency on matters related to drug compounding. FDA has conducted both individual calls with states as well as a series of small group virtual listening sessions with states, held in collaboration with NABP, to address state questions on the MOU and discuss steps states are taking to consider signature. FDA has continued to join NABP monthly calls with states to continue to share information on the MOU and other compounding-related topics.

FDA will establish methods to share additional information about the MOU with states as they consider signature, including answers to frequently asked questions.

In addition to direct calls with states and virtual meetings described above, FDA developed a new website to provide information about the MOU, including instructions on how to pursue signature and a list of frequently asked questions and responses. FDA intends to continue to add questions and responses to this website on a rolling basis.

FDA will explore providing more training that is useful to state pharmacy regulators, including expert-led trainings on compounding quality and pertinent FDA policies. FDA will also continue to make [Compounding Quality Center of Excellence trainings available](#).

FDA continues to offer seats to states at virtual instructor-led trainings offered by the Compounding Quality Center of Excellence and continues to provide on-demand web-based courses accessible to states and the general public. FDA is also working to develop additional recorded webinars that may provide additional training opportunities for states. Finally, FDA plans to offer additional quality-related training at the next upcoming intergovernmental meeting on drug compounding.